Related references
Note: Only part of the references are listed.Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules A Randomized Controlled Trial
Nicoletta Gossger et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study
Maria Elena Santolaya et al.
LANCET (2012)
Meningococcal carriage by age: a systematic review and meta-analysis
Hannah Christensen et al.
LANCET INFECTIOUS DISEASES (2010)
Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis
Karen Edmond et al.
LANCET INFECTIOUS DISEASES (2010)
Human antibody responses to the meningococcal factor H binding protein (LP2086) during invasive disease, colonization and carriage
Dlawer A. A. Ala'Aldeen et al.
VACCINE (2010)
Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease
Han-Qing Jiang et al.
VACCINE (2010)
Sequence Diversity of the Factor H Binding Protein Vaccine Candidate in Epidemiologically Relevant Strains of Serogroup B Neisseria meningitidis
Ellen Murphy et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Global epidemiology of meningococcal disease
Lee H. Harrison et al.
VACCINE (2009)
Epidemiologic and microbiologic characteristics of recurrent bacterial and fungal meningitis in the Netherlands, 1988-2005
Joris J. van Driel et al.
CLINICAL INFECTIOUS DISEASES (2008)
The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance
Guillermo Madico et al.
JOURNAL OF IMMUNOLOGY (2006)
Functional significance of factor H binding to Neisseria meningitidis
Muriel C. Schneider et al.
JOURNAL OF IMMUNOLOGY (2006)
A review of vaccine research and development: Meningococcal disease
Marc P. Girard et al.
VACCINE (2006)
The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB
DR Martin et al.
CLINICAL AND VACCINE IMMUNOLOGY (2006)
Clinical recognition of meningococcal disease in children and adolescents
MJ Thompson et al.
LANCET (2006)
Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands
SC de Greeff et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2006)
Vaccine potential of the Neisseria meningitidis 2086 lipoprotein
LD Fletcher et al.
INFECTION AND IMMUNITY (2004)
Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers
J Bruge et al.
VACCINE (2004)
Share Paper
